TALPHERA INC (TLPH) Stock Price, Forecast & Analysis
USA - NASDAQ:TLPH - US00444T2096 - Common Stock
TLPH Key Statistics, Chart & Performance
The current stock price of TLPH is 1.25 USD. In the past month the price increased by 16.82%. In the past year, price increased by 81.13%.
TLPH Latest News, Press Relases and Analysis
TLPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.62 | 970.39B | ||
| JNJ | JOHNSON & JOHNSON | 18.88 | 471.87B | ||
| MRK | MERCK & CO. INC. | 10.55 | 232.09B | ||
| PFE | PFIZER INC | 7.83 | 142.48B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.11 | 94.95B | ||
| ZTS | ZOETIS INC | 19.06 | 53.55B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.53 | 22.84B | ||
| VTRS | VIATRIS INC | 4.6 | 12.50B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.97 | 10.48B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.07B |
Related stock screener links
About TLPH
Company Profile
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Company Info
TALPHERA INC
1850 Gateway Drive, Suite 175
San Mateo CALIFORNIA US
Employees: 13
Phone: 16502163500
TALPHERA INC / TLPH FAQ
What does TLPH do?
Talphera, Inc. engages in the development and commercialization of therapies used in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 13 full-time employees. The company went IPO on 2011-02-11. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Can you provide the latest stock price for TALPHERA INC?
The current stock price of TLPH is 1.25 USD. The price increased by 19.05% in the last trading session.
Does TALPHERA INC pay dividends?
TLPH does not pay a dividend.
What is the ChartMill rating of TALPHERA INC stock?
TLPH has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does TALPHERA INC belong to?
TALPHERA INC (TLPH) operates in the Health Care sector and the Pharmaceuticals industry.
TLPH Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to TLPH. When comparing the yearly performance of all stocks, TLPH is one of the better performing stocks in the market, outperforming 97.84% of all stocks.
TLPH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLPH. TLPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TLPH Financial Highlights
Over the last trailing twelve months TLPH reported a non-GAAP Earnings per Share(EPS) of -0.38. The EPS increased by 44.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 22.79% | ||
| ROA | 6.67% | ||
| ROE | 12.35% | ||
| Debt/Equity | 0.4 |
TLPH Forecast & Estimates
9 analysts have analysed TLPH and the average price target is 4.25 USD. This implies a price increase of 240% is expected in the next year compared to the current price of 1.25.